Soleno Therapeutics, Inc. (SLNO) P/E Ratio History
Premium ValuationTrading at 135.9x vs 5Y avg 111.6x · 50th percentile · Premium to historical baseline · Data 2025–2026
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, Soleno Therapeutics, Inc. (SLNO) trades at a price-to-earnings ratio of 135.9x, with a stock price of $53.01 and trailing twelve-month earnings per share of $1.81.
The current P/E is 22% above its 5-year average of 111.6x. Over the past five years, SLNO's P/E has ranged from a low of 19.0x to a high of 204.2x, placing the current valuation at the 50th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, SLNO trades at a 514% premium to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, SLNO commands a significant premium over the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SLNO DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SLNO Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
SLNO P/E vs Peers
Commercial Rare Disease Biopharma peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 9.4Lowest | -Best | +68% | |
| $7B | 10.2 | -Best | +264% | |
| $10B | 50.9 | -Best | +128% | |
| $6B | 44.8 | -Best | +2886%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
SLNO Historical P/E Data (2025–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $33.48 | $1.77 | 19.0x | -83% |
| FY2025 Q4 | Dec 31 2025 | $46.30 | $0.23 | 204.2x | +83% |
Average P/E for displayed period: 111.6x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
1+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SLNO — Frequently Asked Questions
Quick answers to the most common questions about buying SLNO stock.
What is SLNO's P/E ratio?
Soleno Therapeutics, Inc. (SLNO) trailing twelve-month P/E ratio is 135.9x, based on TTM diluted EPS of $1.81. The 5-year average P/E is 111.6x and the historical range spans 19.0x to 204.2x.
Is SLNO stock overvalued or undervalued?
SLNO trades at 135.9x P/E, above its 5-year average of 111.6x. The 50th percentile ranking within the 19.0x–204.2x historical range indicates a premium to historical valuation.
Is SLNO stock expensive?
Yes, SLNO is expensive relative to its own history. The current P/E of 135.9x is above the 5-year average of 111.6x and also above the Healthcare sector median of 22.1x. The stock sits at the 50th percentile of its 5-year valuation range.
What is SLNO's historical P/E range?
Over the past 5 years, SLNO's P/E ratio has ranged from 19.0x to 204.2x, with a median of 204.2x and an average of 111.6x. The current P/E of 135.9x places the stock at the 50th percentile of this range. Full historical data spans 2025–2026.
How does SLNO's P/E compare to the S&P 500?
SLNO trades at 135.9x P/E versus the S&P 500 median of 24.4x. The 457% premium to the market typically reflects higher expected earnings growth or quality.
How does SLNO's valuation compare to Healthcare peers?
Soleno Therapeutics, Inc. P/E of 135.9x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is SLNO's PEG ratio?
SLNO PEG ratio is N/A, based on a P/E of 135.9x and EPS growth of 108.9%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is SLNO's earnings yield?
SLNO earnings yield is 0.74%, the inverse of its 135.9x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.